-- 12.30 horas: En Madrid, el ministro de Derechos Sociales, Consumo y Agenda 2030, Pablo Bustinduy, se reúne con ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
Un análisis observacional con más de dos millones de personas señala que los agonistas del GLP-1 reducen el riesgo de sufrir ...
El desarrollo y comercialización de nuevos medicamentos indicados para hacer frente a la obesidad es solo el principio de la ...
Novo Nordisk’s UK unit has been suspended as a ... teams can leverage the At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with ...
Un estudio observacional con más de dos millones de participantes, señala que los agonistas del GLP-1 reducen el riesgo de ...
Énergie Fitness Iberia prepara un programa especial para los usuarios que usan Ozempic u otros medicamentos GLP-1 para perder ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
The Wall Street Journal on MSN1d
Novo Nordisk Shares Surge on New Obesity Drug ResultsNovo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback